<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nicotinic <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> receptors (nAChRs) have been implicated in a number of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>5-<z:chebi fb="0" ids="43448">Iodo</z:chebi>-3-[2(S)-2-azetidinylmethoxy]<z:chebi fb="1" ids="16227">pyridine</z:chebi> (5-I-A-85380) is a novel nAChR marker, binding predominantly to the alpha4beta2 subtype </plain></SENT>
<SENT sid="2" pm="."><plain>This in vitro autoradiography study describes the distribution of 5-[(125)I]-A-85380 binding in post-mortem brain tissue from <z:mpath ids='MPATH_458'>normal</z:mpath> elderly individuals and from cases with age-associated <z:hpo ids='HP_0000726'>dementias</z:hpo> of both neurodegenerative and vascular types </plain></SENT>
<SENT sid="3" pm="."><plain>The binding distribution of 5-[(125)I]-A-85380 in <z:mpath ids='MPATH_458'>normal</z:mpath> brain tissue was found to be consistent with the reported distribution of other high-affinity nicotinic ligands </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to high thalamic and moderate striatal and temporal cortex density, moderate 5-[(125)I]-A-85380 binding was also seen in white matter tracts in cingulate, occipital, and temporal areas, indicating the presence of nAChRs along nerve fiber tracts, which has not been reported in other high-affinity <z:chebi fb="0" ids="47958">nicotinic agonist</z:chebi> distribution studies </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), loss of striatal 5-[(125)I]-A-85380 binding closely parallels the loss of nigrostriatal dopaminergic markers previously observed </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) reduced striatal 5-[(125)I]-A-85380 binding density, comparable to that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, may be a marker of early degeneration in nigrostriatal inputs, while in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) reduced striatal 5-[(125)I]-A-85380 binding could be related to reduced cortical inputs </plain></SENT>
<SENT sid="7" pm="."><plain>The reductions of nAChRs seen in AD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> were not apparent in vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, 5-I-A-85380 is clearly a useful ligand for both in vitro and in vivo single <z:chebi fb="23" ids="30212">photon</z:chebi> emission tomography human studies investigating disease symptoms and progression, response to acetylcholinesterase-inhibiting drugs and in differentiating primary degenerative <z:hpo ids='HP_0000726'>dementia</z:hpo> from VaD </plain></SENT>
</text></document>